By Isabel Demetz
(Reuters) – German packaging and medical equipment maker Gerresheimer, which makes pens used to inject weight loss drugs such as Novo Nordisk’s Wegovy, halved its revenue guidance for 2025 on Wednesday.
The company now expects organic revenue growth in the range of 3% to 5% in 2025, down from the previous range of 7% to 10%. It, however, confirmed the guidance for adjusted core profit margin of around 22%.
The outlook includes the contribution from Bormioli Pharma, whose acquisition was finalised in December and is part of Gerresheimer’s plans to create a new moulded glass business unit.
“The forecast was also influenced by the fact that we are seeing somewhat subdued demand in the cosmetics and food and beverage segments,” a spokesperson told Reuters.
Additionally, Gerresheimer’s customer SQ Innovation will be able to market a combination product with its body-worn drug pump only from October, shifting sales there as well, the spokesperson said.
The company also cut its mid-term guidance for revenue, now expecting the figure to grow in a range of 8% to 10% at compounded annual growth rate, down from a previous projection for growth of equal or above 10%.
Gerresheimer also reported fourth-quarter results broadly in line with market expectations, driven by its plastics and devices division.
The primary packaging glass division showed first signs of a moderate recovery in the glass vial market in the fourth quarter, and has strong order intakes for the second quarter, CEO Dietmar Siemssen said during a conference call.
The company’s share price was little moved by the news on Wednesday, with takeover speculation curbing a potential negative reaction, analysts said.
Earlier in February, Gerresheimer confirmed it was in early-stage discussions about a potential sale of the company, sending its shares up as much as 15%.
($1 = 0.9527 euros)
(Reporting by Isabel Demetz; Editing by Jacqueline Wong, Subhranshu Sahu, Louise Heavens and Emelia Sithole-Matarise)
